Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Dupixent is already approved in the US for a variety of indications, going back to eczema in 2017 (and most recently for the treatment of the rare skin condition prurigo nodularis), but its ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Medically reviewed by Brendan Camp, MD Hives and eczema are two of the most common skin disorders. Hives, clinically known as ...

Managing eczema can be challenging, especially when the weather isn’t on your side. Different climates can either soothe or aggravate your skin, making it essential to understand how your ...

Some people use essential oils to help manage eczema. These include tea tree oil, peppermint oil, and more. However, more research is necessary to understand the possible benefits. Some topicals ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Advanced atopic dermatitis, commonly known as eczema, is a chronic condition that leads to itchiness, inflammation, redness, and flaking of the skin. Though it’s not contagious and the disease can be ...